Annual report pursuant to Section 13 and 15(d)

Business (Details)

v3.19.1
Business (Details)
 1 Months Ended 3 Months Ended 12 Months Ended
Mar. 08, 2019
USD ($)
$ / shares
shares
Mar. 05, 2019
USD ($)
$ / shares
shares
Aug. 17, 2018
USD ($)
$ / shares
shares
Aug. 14, 2017
USD ($)
Apr. 27, 2017
USD ($)
shares
Aug. 31, 2017
USD ($)
Dec. 31, 2018
USD ($)
Sep. 30, 2018
USD ($)
shares
Dec. 31, 2018
USD ($)
product
shares
Dec. 31, 2017
USD ($)
shares
Subsequent Event [Line Items]                    
Number of marketed medical devices | product                 1  
Revenues                 $ 18,326,801 $ 27,813,137
Escrowed cash receivable       $ 3,750,000   $ 3,750,000 $ 0   0 3,752,390
Escrow period       12 months   12 months        
Potential future regulatory milestone payment           $ 20,000,000        
Net (loss) income                 (40,052,810) 11,869,823
Cash flows from operations                 (3,128,102) 12,578,778
Accumulated deficit             (98,218,070)   (98,218,070) (58,165,260)
Cash and cash equivalents             10,646,301   10,646,301 2,472,187
Proceeds from issuance of Series B convertible preferred stock upon warrant exercise, net                 $ 5,685,038 0
2 Neurological Clinical And Preclinical Stage Compounds                    
Subsequent Event [Line Items]                    
Number of products in development | product                 2  
3 Preclinical Therapies                    
Subsequent Event [Line Items]                    
Number of products in development | product                 3  
Preclinical Pediatric Orphan Rare Disease Compound                    
Subsequent Event [Line Items]                    
Number of products in development | product                 1  
License and other revenue                    
Subsequent Event [Line Items]                    
Revenues       $ 25,000,000   $ 25,000,000     $ 0 $ 25,000,000
Private Placement                    
Subsequent Event [Line Items]                    
Proceeds from issuance or sale of equity     $ 3,900,000   $ 4,650,000     $ 3,900,000    
Proceeds from issuance of Series B convertible preferred stock upon warrant exercise, net             $ 5,700,000      
Sale of stock price per share (in dollars per share) | $ / shares     $ 3.91              
Common stock                    
Subsequent Event [Line Items]                    
Issuance of stock (in shares) | shares                 2,349,968 2,301,598
Common stock | Private Placement                    
Subsequent Event [Line Items]                    
Issuance of stock (in shares) | shares     1,000,000   2,345,714     1,000,000    
Subsequent Event | Bought Deal                    
Subsequent Event [Line Items]                    
Number of shares issued (in shares) | shares 1,818,182 1,818,182                
Sale of stock price per share (in dollars per share) | $ / shares $ 5.50 $ 5.50                
Consideration received $ 9,000,000 $ 9,000,000                
Armistice | Subsequent Event | Bought Deal                    
Subsequent Event [Line Items]                    
Number of shares issued (in shares) | shares 363,637 363,637